Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization

Tuberculosis

Volumn 86, Issue 3-4 SPEC. ISS., 2006, Pages 211-217

  Xing, Zhou ^a   Lichty, Brian D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Mouse model; Mucosal immunization; Recombinant virus vectored vaccine; Tuberculosis

Indexed keywords

ADENOVIRUS VECTOR; AG 85A; BCG VACCINE; ESAT 6; MPT 64; PLASMID DNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; CELLULAR IMMUNITY; ENGINEERING; GENE EXPRESSION; HUMAN; IMMUNITY; IMMUNIZATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT;

ACYLTRANSFERASES; ADENOVIRIDAE; ANIMALS; ANTIGENS, BACTERIAL; BCG VACCINE; GENETIC VECTORS; HUMANS; IMMUNIZATION, SECONDARY; MICE; MYCOBACTERIUM TUBERCULOSIS; RESPIRATORY MUCOSA; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VESICULAR STOMATITIS INDIANA VIRUS; VESICULAR STOMATITIS-INDIANA VIRUS;

EID: 33646193580     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2006.01.017     Document Type: Article

References (47)

1. World Health Organization. WHO vaccine preventable diseases-global summary. 2001.
2. Brewer T.F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 31 Suppl 3 (2000) S64-S67
3. Hewinson R.G. TB vaccines for the world. Tuberculosis (Edinburg) 85 (2005) 1-6
4. Wang J., and Xing Z. Tuberculosis vaccines: the past, present and future. Expert Rev Vaccines 1 (2002) 341-354
5. Santosuosso M., Wang J., and Xing Z. The prospects of mucosal vaccination against pulmonary tuberculosis. In: Smithe L.T. (Ed). Focus on tuberculosis research (2005), Nova Science Publishers, Hauppauge 141-164
6. Brennan M.J., Morris S.L., and Sizemore C.F. Tuberculosis vaccine development: research, regulatory and clinical strategies. Expert Opin Biol Ther 4 (2005) 1493-1504
7. Santosuosso M., McCormick S., and Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 18 (2005) 283-291
8. Karonga prevention trial group. Randomized controlled trial of single BCG, repeated BCG or combined BCG and killed Mycobacterium leprae vaccine for leprosy and tuberculosis in Malawi. Lancet 348 (1996) 17-24
9. Buddle B.M., Wedlock D.N., Parlane N.A., Corner L.A., De Lisle G.W., and Skinner M.A. Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination. Infect Immun 71 (2003) 6411-6419
10. Andersen P. TB vaccines: progress and problems. Trends Immunol 22 (2001) 160-168
11. Doherty T.M., Olsen A.W., van Pinxteren L., and Andersen P. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect Immun 70 (2002) 3111-3121
12. Pachuk C.J., McCallus D.E., Weiner D.B., and Satishchandran C. DNA vaccines-challenges in delivery. Curr Opin Mol Ther 2 (2000) 188-198
13. Cardona P.J., Amat I., Gordillo S., Arcos V., Guirado E., Diaz J., et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 23 (2005) 1393-1398
14. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., and Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171 (2003) 1602-1609
15. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173 (2004) 6357-6365
16. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 (2004) 1240-1244
17. Williams A., Goonetilleke N.P., McShane H., Clark S.O., Hatch G., Gilbert S.C., et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in Guinea pigs. Infect Immun 73 (2005) 3814-3816
18. Rubin B.A., and Rorke L.B. Adenovirus vaccines. In: Plotkin S.A., and Mortimer E.A. (Eds). Vaccines (1998), Saunders, Philadelphia 492-512
19. Bramson J.L., Graham F.L., and Gauldie J. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Biotechnol 6 (1995) 590-595
20. St George J.A. Gene therapy progress and prospects: adenoviral vectors. Gene Ther 10 (2003) 1135-1141
21. Xing Z., Braciak T., Ohkawara Y., Sallenave J.-M., Foley R., Sime P.J., et al. Gene Transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. J Leukoc Biol 59 (1996) 481-488
22. Xing Z., Stampfli M.R., and Gauldie J. Transient transgenic approaches for investigating the role of granulocyte-macrophage colony-stimulating factor in pulmonary inflammatory and immune diseases. Methods Mol Med 4 (2000) 161-178
23. Tatsis N., and Ertl H.C.J. Adenovirus as vaccine vectors. Mol Ther 10 (2004) 616-629
24. Emini E. Ongoing development and evaluation of a potential HIV-1 vaccine using a replication-defective adenoviral vector. In: KeyStone conference on HIV vaccines, Banff, March 29-April 4, 2003 [Abstract 012].
25. Perperi L. HVTN vaccines in development: nonreplicating adenoviral vector vaccines. http://chi.ucsf.edu/vaccines, 2005.
26. Xing Z., Ohkawara Y., Jordana M., Graham F.L., and Gauldie J. Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions. J Clin Invest 97 (1996) 1102-1110
27. Sime P.J., Xing Z., Graham F.L., Csaky K.G., and Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor ß-1 induces prolonged severe fibrosis in rat lung. J Clin Invest 100 (1997) 768-776
28. Lei X.F., Ohkawara Y., Stämpfli M.R., Gauldie J., Croitoru K., Jordana M., et al. Compartmentalized transgene expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) in mouse lung enhances allergic airways inflammation. Clin Exp Immunol 113 (1998) 157-165
29. Xing Z., Gauldie J., Tremblay G.M., Hewlett B.R., and Addison C. Intradermal transgenic expression of granulocyte-macrophage colony-stimulating factor induces neutrophilia, epidermal hyperplasia, Langerhans' cell/macrophage accumulation and dermal fibrosis. Lab Invest 77 (1997) 615-622
30. Yang T.C., Dayball K., Wan Y.H., and Bramson J. Detailed analysis of the CD8 T cell response following adenovirus vaccination. J Virol 77 (2003) 13407-13411
31. Xing Z., Ohkawara Y., Jordana M., Graham F.L., and Gauldie J. Adenoviral vector-mediated IL-10 expression in vivo: intramuscular gene transfer inhibits cytokine responses in endotoxemia. Gene Ther 4 (1997) 140-149
32. Santosuosso M., Zhang X., McCormick S., Wang J., Hitt M., and Xing Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol 174 (2005) 7986-7994
33. Lichty B.D., Power A.T., Stojdl D.F., and Bell J.C. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 10 (2004) 210-216
34. Flanagan E.B., Zamparo J.M., Ball L.A., Rodriguez L.L., and Wertz G.W. Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J Virol 75 (2001) 6107-6114
35. Roberts A., Buonocore L., Price R., Forman J., and Rose J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73 (1999) 3723-3732
36. Wagner R.R., and Rose J.K. Rhabdoviridae: the viruses and their replication. In: Fields B.N., and Knipe D.M. (Eds). Fields virology (1996), Lippincott-Raven, New York 1121-1136
37. von Kobbe C., van Deursen J.M., Rodrigues J.P., Sitterlin D., Bachi A., Wu X., et al. Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell 6 (2000) 1243-1252
38. Petersen J.M., Her L.S., Varvel V., Lund E., and Dahlberg J.E. The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol 20 (2000) 8590-8601
39. Petersen J.M., Her L.S., and Dahlberg J.E. Multiple vesiculoviral matrix proteins inhibit both nuclear export and import. Proc Natl Acad Sci USA 98 (2001) 8590-8595
40. Stojdl D.F., Lichty B.D., tenOever B.R., Paterson J.M., Power A.T., Knowles S., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4 (2003) 263-275
41. Lawson N.D., Stillman E.A., Whitt M.A., and Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92 (1995) 4477-4481
42. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., Buonocore L., et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72 (1998) 4704-4711
43. Schlereth B., Rose J.K., Buonocore L., ter Meulen V., and Niewiesk S. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 74 (2000) 4652-4657
44. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 (2001) 539-549
45. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11 (2005) 786-790
46. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., and Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340 (2005) 174-182
47. Vordermeier H.M., Huygen K., Singh M., Hewinson R.G., and Xing Z. Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing mycobacterial antigen 85A and BCG. Infect Immun 74 (2006) 1416-1418